Your browser doesn't support javascript.
loading
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
Quintana, Ángela; Peg, Vicente; Prat, Aleix; Moliné, Teresa; Villacampa, Guillermo; Paré, Laia; Galván, Patricia; Dientsmann, Rodrigo; Schmid, Peter; Curigliano, Giuseppe; Muñoz-Couselo, Eva; Perez-García, José; Marti, Merce; Blanco-Heredia, Juan; Anjos, Carla Dos; Vazquez, Miguel; De Mattos-Arruda, Leticia; Cortés, Javier.
Afiliação
  • Quintana Á; Vall D'Hebrón Institute of Oncology, Barcelona, Spain; Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Peg V; Universidad Autónoma de Barcelona, Barcelona, Spain; Department of Pathology, Vall D'Hebron University Hospital, Barcelona, Spain; Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
  • Prat A; Medical Oncology Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics Group, IDIBAPS, Barcelona, Spain.
  • Moliné T; Department of Pathology, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Villacampa G; Oncology Data Science (ODysSey Group), Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Paré L; Translational Genomics and Targeted Therapeutics Group, IDIBAPS, Barcelona, Spain.
  • Galván P; Medical Oncology Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics Group, IDIBAPS, Barcelona, Spain.
  • Dientsmann R; Oncology Data Science (ODysSey Group), Vall D'Hebron Institute of Oncology, Barcelona, Spain.
  • Schmid P; Barts Cancer Institute, Queen Mary University London, United Kingdom.
  • Curigliano G; European Institute of Oncology, IRCCS, And University of Milano, Milan, Italy.
  • Muñoz-Couselo E; Vall D'Hebrón Institute of Oncology, Barcelona, Spain; Medical Oncology Hospital Vall D'Hebrón, Barcelona, Spain.
  • Perez-García J; IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain.
  • Marti M; Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Blanco-Heredia J; IrsiCaixa, Hospital Universitari Trias I Pujol, Badalona, Spain.
  • Anjos CD; IrsiCaixa, Hospital Universitari Trias I Pujol, Badalona, Spain.
  • Vazquez M; Barcelona Supercomputing Center, Barcelona, Spain.
  • De Mattos-Arruda L; IrsiCaixa, Hospital Universitari Trias I Pujol, Badalona, Spain. Electronic address: ldemattos@irsicaixa.es.
  • Cortés J; Vall D'Hebrón Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Electronic address: jacortes@vhio.net.
Eur J Cancer ; 148: 134-145, 2021 05.
Article em En | MEDLINE | ID: mdl-33743482
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with unmet medical needs. Several studies have proved that high levels of tumor infiltrating lymphocytes (TILs) at diagnosis of TNBC confer better prognosis and patients respond better to specific chemotherapies. Nonetheless, current evidence suggests that only 15% of TNBC patients have very high levels of TILs, and another 15% lacks TILs. One possible reason to explain why patients have low TILs at diagnosis is that lymphocytes might be deactivated by an immune checkpoint in local lymph nodes, provoking their retention in there as they are unresponsive to other immune stimuli. We have identified 15 high TILs (≥50%) and 20 low TILs (≤5%) TNBC patients with localised tumour (T1c-T2N0M0) and compared the protein expression of five immune checkpoints in lymph nodes. We have also performed a customised 50-immune gene NanoString expression panel, the NanoString 360 Breast Cancer panel, and whole exome sequencing for mutation and neoantigen load analyses. In low TILs, we observed higher expression of CTLA-4 in local lymph nodes, which could explain why lymphocytes get retained in there and do not migrate to tumour. These patients have also higher neoantigen load and higher expression of B7.H3 and B7.H4 in the tumour. In high TILs, we observed more PD-L1+ tumour cells and more expanded humoral response. These results could provide a strategy to revert low tumour immune infiltration at diagnosis of TNBC, improving their prognosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Linfócitos do Interstício Tumoral / Neoplasias de Mama Triplo Negativas / Linfonodos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Linfócitos do Interstício Tumoral / Neoplasias de Mama Triplo Negativas / Linfonodos Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article